Relmada Therapeutics (RLMD) Change in Account Payables (2012 - 2026)
Relmada Therapeutics (RLMD) posted quarterly Change in Account Payables of $1.8 million for Q1 2026, up 161.5% year-over-year from $673967.0 in Q1 2025, and up 1421.43% quarter-over-quarter from $115842.0 in Q4 2025.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Change in Account Payables (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Change in Account Payables for 15 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 161.5% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $2.1 million (up 152.66% YoY), while the FY2025 annual figure was -$2.6 million, down 510.15% from the prior year.
- Change in Account Payables improved to $1.8 million in Q1 2026 per RLMD's latest filing, from $115842.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.2 million in Q2 2022 and bottomed at -$3.5 million in Q3 2022.
- Historically, Change in Account Payables has averaged -$88793.8 across 5 years, with a median of $96901.0 in 2025.
- On a YoY basis, Change in Account Payables climbed as much as 300.38% in 2024 and fell as far as 335.04% in 2024.
- Relmada Therapeutics' Change in Account Payables stood at $1.2 million in 2022, then plunged by 45.33% to $649257.0 in 2023, then soared by 174.93% to $1.8 million in 2024, then slumped by 93.51% to $115842.0 in 2025, then soared by 1421.43% to $1.8 million in 2026.
- Business Quant data shows RLMD's Change in Account Payables at $1.8 million in Q1 2026, $115842.0 in Q4 2025, and $91191.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | -922,211.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -922,211.00 |
| Mar 31, 2026 | 1.76 Mn |
| Dec 31, 2025 | 115,842.00 |
| Sep 30, 2025 | 91,191.00 |
| Jun 30, 2025 | 96,901.00 |
| Mar 31, 2025 | -2.87 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Sep 30, 2024 | -1.83 Mn |
| Jun 30, 2024 | -1.01 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2023 | 649,257.00 |
| Sep 30, 2023 | -2.00 Mn |
| Jun 30, 2023 | 431,651.00 |
| Mar 31, 2023 | -839,971.00 |
| Dec 31, 2022 | 1.19 Mn |
| Sep 30, 2022 | -3.47 Mn |
| Jun 30, 2022 | 3.22 Mn |
| Mar 31, 2022 | -522,353.00 |
| Dec 31, 2021 | -1.52 Mn |
| Sep 30, 2021 | 2.25 Mn |